NORD Intervention In EPO Appeal Seeks Consideration Of Amgen Epogen Cost
Executive Summary
The National Organization for Rare Disorders is attempting to have the issue of drug pricing play a role in the appeal of the erythropoietin patent case Amgen v. Aventis/Transkaryotic Therapies.